Abstract
Introduction
The normalization of cellular glucose assimilation is the basic aim of metabolic therapy in type 2 diabetes mellitus (T2DM). It requires parallel changes in the process of cellular glucose transport (CGT). Therefore the level of CGT could be regarded as a therapeutic target for oral hypoglycemic drugs in T2DM. To explore this hypothesis, CGT levels before and after sulfonylurea therapy were investigated. Peripheral blood lymphocytes were used as a cell model for testing CGT.
Materials and Methods
CGT was assessed by experimental in vitro tests allowing timed comparative observation of the transport process during the incubation of lymphocytes with 2-[3H(G)] glucose under basal conditions and after the addition of sulfonylurea or sulfonylurea plus insulin. The incubation tests were performed at baseline in 28 persons with newly diagnosed, therapy-naive T2DM and in 20 control subjects. In the diabetic patients the tests for CGT were repeated after 3 months of sulfonylurea therapy. The level of glucotransporter 4 (GLUT4) expression was also assessed by flow cytometry before and after the therapy.
Results
Before treatment, CGT was significantly lower in the subjects with T2DM. The cells responded to the addition of sulfonylurea by a moderate increase in CGT. This response was augmented by the addition of insulin to sulfonylurea in the culture medium.
Conclusions
The three-month therapy with sulfonylurea resulted in a significant increase in CGT in all types of culture tests. This sulfonylurea-related improvement in CGT was associated with a near normalization of GLUT4 expression in the cells.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.Avoid common mistakes on your manuscript.
References
Almer LO (1984) Effects of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes. Thromb Res 35: 19–25
Armitage P (1971) Statistical methods in medical research, 3rd ed. Blackwell Scientific Publication, Oxford
Chakrabarti R, Jung CY, Lee TP et al (1994) Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol 152: 2660–2668
Curto M, Piccinini M, Rabbone I et al (1997) G proteins and regulation of pyruvate dehydrogenase activity by insulin in human circulating lymphocytes. Int J Biochem Cell Biol 29: 1207–1217
Czech MP, Corvera S (1999) Signaling mechanisms that regulate glucose transport. J Biol Chem 274: 1865–1868
Daneman D, Zinman B, Elliot ME et al (1992) Insulin-stimulated transport in circulating mononuclear cells from nondiabetic and IDDM subjects. Diabetes 41: 227–234
Dimitriadis G, Maratou E, Boutati E et al (2005) Evaluation of glucose transport and its regulation by insulin in human monocytes using flow cytometry. Cytometry A 64: 27–33
Estrada DE, Elliot E, Zinman B et al (1994) Regulation of glucose transport and expression of GLUT 3 transporters in human mononuclear cells; studies in cells from insulin-dependent diabetic and nondiabetic individuals. Metabolism 43: 591–598
Fava D, Cassone-Faldetta M, Laurenti O et al (2002) Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilatation in type 2 diabetes. Diabet Med 19: 752–757
Galuska D, Nolte LA, Zierath JR et al (1994) Effects of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtainer from patients with NIDDM.. Diabetologia 37: 826–832
Gram J, Jespersen J, Kold A (1988) Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated patients. Metabolism 37: 937–943
Itoh M, Omi H, Okouchi M et al (2003) The mechanism of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration. J Diabetes Complications 17: 22–26
Jennings PE, Scott NA, Santabadi AR et al (1992) Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessments. Metabolism 41: 36–39
Joshi N, Caputo GM, Weiteleamp MR et al (1999) Infection in patients with diabetes mellitus. N Engl J Med 341: 1906–1912
Kahn BB (1996) Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes 45: 1644–1654
Kaliman P, Vinals F, Testar X et al (1995) Disruption of GLUT1 glucose carrier trafficking in L6E9 and So18 myoblast by the phosphatidylinositol 3-kinase inhibitor wortmannin. Biochem J 312:471–477
Korgun ET, Demir R, Sedlmayr P et al (2002) Sustained hypoglycemia affects glucose transporter expression of human blood leukocytes. Blood Cells Mol Dis 28: 152–159
Longo M, Elsas LJ (1998) Human glucose transporters Adv Pediatr 45:293–313
Matthaei S, Stumvoll M, Kellerer M et al (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21: 585–618
O’Brien RC, Luo M, Balazs N et al (2000) In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 14: 201–206
Otton R, Mendonca JR, Curi R (2002) Diabetes causes marked changes in lymphocyte metabolism. J Endocrinol 174: 55–61
Phay JE, Hussain HB, Moley JF (2000) Cloning and expression analysis of a novel member of the facilitative glucose transporters family, SLC2A9 (GLUT9). Genomics 66: 217–220
Piątkiewicz P, Czech A, Tatoń J (2007) Glucose transport in human peripheral blood lymphocytes influenced by diabetes mellitus. Arch Immunol Ther Exp 55: 119–126
Pulido N (2000) Gliclazide stimulates glucose transport in skeletal muscle through PKC activation. Diabetologia 43(suppl 1): 706
Pulido N, Romero R., Suarez AI et al (1996) Sulfonylureas stimulate glucose uptake through GLUT4 transporter translocation in rat skeletal muscle. Biochem Biophys Res Commun 228: 499–504
Pulido N, Suarez A, Casanova B et al (1997) Gliclazide treatment of streptozotocin diabetic rat restores GLUT4 protein content and basal glucose uptake in skeletal muscle.. Metabolism 46(suppl 1): 10–13
Shepherd PR, Kahn BB (1999) Glucose transporters and insulin action – implications for insulin resistance and diabetes mellitus. N Engl J Med 341: 248–257
Shulman GI (2000) Cellular mechanism of insulin resistance. J Clin Invest 106: 171–176
Szablewski L, Oleszczuk B, Malejczyk J et al (2000) Facilitative glucose transporters in rat chondrocycytes. Eur J Cell Biol 79(suppl 52): 113
Tsiani E, Ramlal T, Leiter LA et al (1995) Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136: 2505–2512
Vestergaard H, Weinreb JE, Rosen AS et al (1995) Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study. J Clin Endocrinol Metab 80: 270–275
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Czech, A., Piątkiewicz, P. & Tatoń, J. Cellular glucose transport and glucotransporter 4 expression as a therapeutic target: clinical and experimental studies. Arch. Immunol. Ther. Exp. 57, 467–473 (2009). https://doi.org/10.1007/s00005-009-0052-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-009-0052-7